UK markets closed

AGEN Aug 2024 0.500 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.20000.0000 (0.00%)
As of 10:12AM EDT. Market open.
Full screen
Previous close0.2000
Open0.2000
Bid0.0000
Ask0.0000
Strike0.50
Expiry date2024-08-16
Day's range0.2000 - 0.2000
Contract rangeN/A
Volume1
Open interest1.16k
  • Business Wire

    Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

    LEXINGTON, Mass., May 23, 2024--Agenus Inc. ("Agenus") (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, and Robin Taylor, Chief Commercial Officer, will participate in a fireside chat and investor one-on-ones at the upcoming Goldman Sachs Global Healthcare Conference on June 10th – 13th in Miami Beach, Florida. The fireside chat will take place at 8:00 a.m. ET on June 12th.

  • Business Wire

    FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer

    LEXINGTON, Mass., May 16, 2024--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the U.S. Food and Drug Administration (FDA) to discuss the botensilimab plus balstilimab (BOT/BAL) combination therapy studies in patients with relapsed/refractory metastatic colorectal cancer that is not MSI-high or dMMR (r/r MSS mCRC), as well as the

  • Insider Monkey

    Agenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript

    Agenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript May 7, 2024 Agenus Inc. beats earnings expectations. Reported EPS is $-3.04104, expectations were $-3.1. AGEN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by, and welcome to […]